Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving Average – Should You Sell?

Coherus Oncology, Inc. (NASDAQ:CHRS) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.44 and traded as high as $2.16. Coherus Oncology shares last traded at $2.06, with a volume of 1,478,342 shares.

Wall Street Analysts Forecast Growth

A number of research firms have commented on CHRS. Wall Street Zen raised Coherus Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Oppenheimer initiated coverage on Coherus Oncology in a research note on Thursday, January 22nd. They set an “outperform” rating and a $10.00 target price on the stock. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Coherus Oncology presently has an average rating of “Hold” and an average target price of $5.51.

Coherus Oncology Stock Performance

The company has a quick ratio of 1.23, a current ratio of 1.24 and a debt-to-equity ratio of 0.42. The firm has a market cap of $248.99 million, a P/E ratio of 1.55 and a beta of 0.99. The business has a fifty day simple moving average of $1.61 and a 200-day simple moving average of $1.44.

Hedge Funds Weigh In On Coherus Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jefferies Financial Group Inc. boosted its position in shares of Coherus Oncology by 21.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 395,190 shares of the biotechnology company’s stock worth $561,000 after purchasing an additional 69,565 shares in the last quarter. ProShare Advisors LLC raised its stake in Coherus Oncology by 36.3% during the fourth quarter. ProShare Advisors LLC now owns 24,718 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 6,583 shares during the last quarter. Bronte Capital Management Pty Ltd. bought a new stake in Coherus Oncology in the fourth quarter worth $27,000. Kestra Private Wealth Services LLC purchased a new stake in shares of Coherus Oncology in the fourth quarter worth $28,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Coherus Oncology in the 4th quarter worth about $28,000. Institutional investors own 72.82% of the company’s stock.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.